1. What conditions has Niacinamide been studied for?

• Skin hyperpigmentation disorders: post-inflammatory hyperpigmentation (PIH) and melasma (as a depigmenting/anti-pigmenting agent in dermatology/cosmeceuticals).

• Skin aging / senescence-related skin changes: discussed as a topical active that reduces inflammation and mitigates effects of senescence in aging skin.

• Acne vulgaris: included among dermocosmetic active ingredients used to target aspects of acne pathophysiology and support skin health.

• Acute kidney injury (AKI) (ischemia-related and toxic models): studied as the NAD precursor nicotinamide (NAM) in animal models, including treatment after established injury and prevention in another toxic model.

• Heart failure with preserved ejection fraction (HFpEF): not directly as niacinamide supplementation in the study, but the pathway is implicated—IPA supplementation restored nicotinamide/NAD salvage via suppression of NNMT.

• Autosomal dominant polycystic kidney disease (ADPKD): mentioned among supplements with uncertain clinical benefit and not currently recommended based on limited evidence.

• Cancer/radiotherapy response (small cell lung cancer, SCLC): a niacinamide analog (6-amino niacinamide) was used experimentally to enhance radiosensitization in mechanistic studies (not standard niacinamide supplementation).

• Vitamin B3 deficiency (pellagra): vitamin B3 is required for NAD synthesis; niacinamide is one form of vitamin B3 (the study references deficiency and NAD synthesis generally).

2. Does it work in treating those conditions? Summarize the evidence.

• AKI (animal evidence: supportive): In post-ischemic AKI models, local deficiency of the NAD precursor niacinamide occurred in Pgc1α knockout mice, and exogenous NAM improved local NAD levels, reduced fat accumulation, and improved renal function. NAM also reversed established ischemic AKI and prevented AKI in an unrelated toxic model in the reported experiments. This is strong preclinical evidence, but it is not human clinical trial evidence.

• Melasma/hyperpigmentation (human-oriented but mixed strength): A systematic review/meta-analysis of antioxidants reported that niacinamide was among antioxidants “showing promise” in reducing pigmentation in melasma, but the meta-analysis highlighted vitamin C as showing significant effects; niacinamide’s effect size and certainty are not clearly established from the study alone.

• PIH (clinical use rationale; evidence not quantified in abstract): A PIH review lists niacinamide among agents used for dyschromias/PIH and notes that depigmenting agents act via different mechanisms. However, the study does not provide trial outcomes or effect sizes for niacinamide specifically.

• Skin aging/senescence (review-level support): A review of “core” topical actives states that niacinamide reduces inflammation and mitigates effects of senescence. This supports plausibility and use, but the study does not provide specific clinical endpoints or trial results.

• Acne (supportive adjunct/dermocosmetic role): A dermatology-focused publication describes niacinamide-containing dermocosmetics as targeting aspects of acne pathophysiology and supporting barrier function, including use as monotherapy for mild acne and relapse prevention. The study does not provide comparative efficacy data.

• ADPKD (insufficient/uncertain): A review explicitly states that supplementation with … niacinamide has “uncertain clinical benefit” in ADPKD and that use of these supplements is not currently recommended due to limited clinical evidence and uncertain long-term consequences.

• HFpEF (indirect evidence only): The HFpEF abstract supports the importance of the nicotinamide/NAD salvage pathway (IPA supplementation suppressed NNMT and restored nicotinamide/NAD), but it does not test niacinamide supplementation itself. Therefore, it is mechanistic/indirect rather than direct evidence for niacinamide treatment in HFpEF.

• SCLC radiosensitization (not clinical supplementation): The study reports that radiosensitization could be enhanced by 6-amino niacinamide (a niacinamide analog) in a mechanistic context involving PPP/NADPH/ROS. This does not establish niacinamide as a cancer therapy and should not be extrapolated to routine supplementation.

3. What health benefits does it have?

• NAD metabolism support (core biochemical role): Niacinamide (nicotinamide) is described as a hydrosoluble vitamin with essential metabolic functions and a pivotal role in NAD-related biology. In AKI models, boosting NAD via NAMPT and related pathways was linked to improved renal recovery.

• Renal stress resistance and recovery (preclinical): In mouse AKI models, exogenous NAM increased local NAD, reduced renal fat accumulation, improved renal function, and could reverse established ischemic injury; mechanistically linked to β-hydroxybutyrate and prostaglandin (PGE2) signaling in the study.

• Skin benefits (topical/cosmetic-dermatologic):

  • Hyperpigmentation: included among agents used for PIH and identified as a promising antioxidant for melasma in a systematic review.

  • Anti-inflammatory / anti-senescence: described as reducing inflammation and mitigating effects of senescence in skin aging-focused review content.

  • Acne-supportive care: included among dermocosmetic actives used to support acne management and potentially help prevent relapses (abstract-level description).

• Potential cardiometabolic relevance (indirect): In HFpEF models, restoring nicotinamide/NAD salvage (via IPA’s suppression of NNMT) was associated with improved diastolic function and reduced oxidative stress/inflammation, suggesting NAD salvage may be a beneficial target—though this is not direct niacinamide supplementation evidence.

4. Does it have any downsides or side effects?

The studies reviewed here contain limited direct safety/adverse-event reporting for niacinamide itself, especially in humans. Key cautions that can be supported from the studies are mainly about evidence gaps and context-specific concerns rather than specific side-effect rates.

• Uncertain benefit and unknown long-term consequences in ADPKD: The ADPKD review states that niacinamide supplementation has uncertain clinical benefit and that supplement use is not currently recommended, emphasizing limited clinical evidence and uncertain long-term consequences in this population.

• Context-dependent metabolic effects (mechanistic caution): In the SCLC radioresistance study, a niacinamide analog (6-amino niacinamide) was used to enhance oxidative stress and cell death by affecting PPP/NADPH/ROS balance. This does not demonstrate harm from niacinamide in typical use, but it highlights that manipulating NAD/NADPH-related pathways can have potent biological effects depending on context and compound.

• General limitation: For dermatologic uses (PIH, melasma, acne, aging), the studies do not report specific adverse events (e.g., irritation rates), so side-effect conclusions cannot be drawn from these excerpts alone.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

• PGC1α (PPARGC1A) deficiency model suggests genotype-dependent benefit (preclinical): In the AKI abstract, Pgc1α(-/-) mice developed local niacinamide deficiency after ischemia and had impaired recovery; exogenous NAM improved NAD levels and renal function in this genotype. This implies that genetic or functional impairment in the PGC1α pathway could increase dependence on NAD precursors like niacinamide during stress. However, this is an animal knockout model and not a validated human pharmacogenomic marker for supplementation.

• NNMT pathway relevance (indirect; not a tested genotype): In HFpEF models, IPA suppressed NNMT and restored nicotinamide/NAD salvage. This suggests that variation in NNMT activity could plausibly influence nicotinamide availability and NAD salvage, but the study does not evaluate NNMT genetic variants or niacinamide response by genotype.

• ADPKD genotype (PKD1/PKD2) does not establish niacinamide responsiveness: Although ADPKD is genetic, the review concludes niacinamide supplementation has uncertain clinical benefit and is not recommended; it does not identify any genotype subgroup that benefits or is harmed.

Overall, the studies provide mechanistic and animal-model hints that genetic differences in NAD biogenesis regulation (e.g., PGC1α-related pathways) could modify response, but there is no direct human pharmacogenomic evidence in the provided material.

Niacin

Across the studies reviewed here, niacin (vitamin B3) research is most developed in (1) cardiovascular prevention and lipid modification—particularly pharmacologic niacin used to raise HDL cholesterol, often in the context of statin therapy—and (2) population-based nutritional epidemiology linking dietary niacin intake to health outcomes. Additional, but less clinically mature, areas include mechanistic and review-oriented work on niacin/NAD biology and emerging interest in neurological indications, as well as broader “natural product” contexts (e.g., bee pollen as a variable dietary source of niacin and other bioactives). There is also descriptive public health research on supplement use patterns (including niacin intake from prenatal supplements) in specific populations such as pregnant and lactating women.

The strongest evidence in these studies comes from large meta-analyses of randomized trials evaluating HDL-raising interventions: despite reliably increasing HDL, niacin did not reduce all-cause mortality, coronary heart disease mortality, myocardial infarction, or stroke in patients already treated with statins; any apparent benefit for non-fatal myocardial infarction was confined to older “pre-statin era” trials, suggesting limited incremental value in contemporary statin-treated populations. In contrast, observational analyses suggest potentially favorable associations between higher dietary niacin intake and certain outcomes: a cross-sectional NHANES analysis reported an L-shaped association with migraine prevalence with an inflection around ~21 mg/day, and a cohort analysis in adults with NAFLD found higher dietary niacin intake associated with lower all-cause mortality (with no clear association for CVD mortality). These observational findings support hypothesis generation but do not establish causality.

Key gaps include the need for well-designed prospective studies and randomized controlled trials to test whether increasing dietary niacin (or specific niacin forms) causally reduces migraine risk or improves outcomes in NAFLD, and to clarify dose–response relationships and thresholds suggested by spline/L-shaped patterns. More research is also needed to reconcile differences between dietary niacin associations and pharmacologic niacin trial outcomes, including potential confounding by overall diet quality, baseline nutritional status, and comedications (notably statins), as well as safety and risk–benefit tradeoffs of supplementation in diverse populations. For natural products such as bee pollen, the major limitation is compositional variability; rigorous standardization and long-term clinical studies are required before therapeutic claims can be substantiated.

Nicotinamide

Human research on nicotinamide (niacinamide; NAM) spans two main domains: (1) dermatology, where NAM is studied primarily as a topical agent for acne and photoaging/hyperpigmentation, and (2) metabolism, where NAM is considered alongside other NAD⁺ precursors (notably nicotinic acid, nicotinamide riboside, and nicotinamide mononucleotide) in trials assessing lipid and glucose outcomes. The dermatology literature includes randomized, double-blind comparisons of 4% topical nicotinamide gel versus 1% clindamycin for moderate inflammatory acne, and controlled facial “split-face” or paired-design studies of 2–5% topical niacinamide for hyperpigmentation, skin sallowness, wrinkles, and elasticity. Mechanistic work in pigmentation models suggests niacinamide reduces visible pigmentation primarily by inhibiting melanosome transfer rather than inhibiting tyrosinase activity.

The strongest evidence in the studies reviewed here supports topical niacinamide as an effective, well-tolerated dermatologic intervention. Across acne trials, 4% nicotinamide gel produced improvements comparable to topical clindamycin over ~8 weeks, with the added theoretical advantage of avoiding antimicrobial resistance pressure. For photoaging and dyschromia, controlled clinical studies report statistically significant improvements in fine lines/wrinkles, hyperpigmented spots, redness/blotchiness, sallowness (yellowing), and measures of elasticity after ~4–12 weeks of twice-daily application (typically 5% niacinamide), consistent with supportive mechanistic findings on pigment transfer. In contrast, evidence for systemic metabolic effects attributable specifically to nicotinamide is less definitive in the cited meta-analysis of NAD⁺ precursors: overall, NAD⁺ precursor supplementation was associated with improved lipid parameters but also higher fasting glucose, and subgroup analyses indicated nicotinic acid (not nicotinamide) drove the most pronounced lipid effects; the meta-analysis also noted limited numbers of studies for NR and NAM, constraining inference for NAM.

Key gaps include the need for more high-quality, adequately powered randomized trials that isolate nicotinamide (rather than pooling across heterogeneous NAD⁺ precursors) to clarify its systemic effects on lipids, glycemia, and cardiometabolic outcomes, including differential effects in healthy participants versus those with dyslipidemia or cardiovascular disease. In dermatology, additional research would strengthen external validity by expanding to more diverse populations and longer follow-up, standardizing endpoints, and directly comparing niacinamide with other non-antibiotic anti-inflammatory acne therapies and established pigment-modulating agents. Finally, translational work on nicotinamide metabolites (e.g., 1-methylnicotinamide) is suggestive of anti-inflammatory potential, but requires rigorous clinical evaluation to determine comparative efficacy, safety, and indications relative to nicotinamide itself.

Vitamin B3 in Energy Metabolism and Disease Prevention

Vitamin B3, also known as Niacin, plays a crucial role in energy metabolism by contributing to the synthesis of NADH for oxidative phosphorylation within the mitochondria. B3 is therefore integral to the generation of energy in the body.

Impact on Mitochondrial Function

Deficiencies in B vitamins, including B3, can lead to impaired mitochondrial function, with potential symptoms being alleviated by supplemental B vitamins.

Antioxidant Properties

B vitamins may act as antioxidants, possibly offering protection against oxidative stress, which is linked to various age-related diseases.

Nicotinamide and Skin Cancer Prevention

A Phase 3 trial focused on nicotinamide (a form of Vitamin B3) demonstrated a 23% reduction in new nonmelanoma skin cancers in high-risk individuals. It was effective and safe during the 12-month treatment period, but protective effects did not continue after stopping the treatment.

Association with Lung Cancer Risk

While B vitamins are crucial for one-carbon metabolism, high doses of individual supplements of vitamin B6 and B12, particularly in men and smokers, have been associated with an increased risk of lung cancer.

Conclusion

Vitamin B3 is essential for mitochondrial energy production and may help prevent certain diseases, such as nonmelanoma skin cancers. However, the long-term use of high doses of certain B vitamins requires caution due to potential increased cancer risks.

References:

1. Mitochondrial function and toxicity: role of the B vitamin family on mitochondrial energy metabolism
2. Folate, vitamin B12 and vitamin B6 and one carbon metabolism
3. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention
4. Long-Term, Supplemental, One-Carbon Metabolism-Related Vitamin B Use in Relation to Lung Cancer Risk in the Vitamins and Lifestyle (VITAL) Cohort
5. VITamins And Lifestyle cohort study: study design and characteristics of supplement users
6. Folate and colorectal cancer: an evidence-based critical review
7. The effects of long-term daily folic acid and vitamin B12 supplementation on genome-wide DNA methylation in elderly subjects
8. One-Carbon Metabolism in Prostate Cancer: The Role of Androgen Signaling
9. Mechanistic Insights into the Multiple Functions of Niacinamide: Therapeutic Implications and Cosmeceutical Applications in Functional Skincare Products.
   Cíntia Marques, Farid Hadjab, Alexandre Porcello, Kelly Lourenço, Corinne Scaletta, Philippe Abdel-Sayed, Nathalie Hirt-Burri, Lee Ann Applegate, Alexis Laurent (2024) - Antioxidants (Basel, Switzerland)
10. Indole-3-Propionic Acid Protects Against Heart Failure With Preserved Ejection Fraction.
    Yu-Chen Wang, Yen Chin Koay, Calvin Pan, Zhiqiang Zhou, Wilson Tang, Jennifer Wilcox, Xinmin S Li, Alexia Zagouras, Francine Marques, Hooman Allayee, Federico E Rey, David M Kaye, John F O'Sullivan, Stanley L Hazen, Yang Cao, Aldons J Lusis (2024) - Circulation research
11. Mechanistic Basis and Clinical Evidence for the Applications of Nicotinamide (Niacinamide) to Control Skin Aging and Pigmentation.
    Yong Chool Boo (2021) - Antioxidants (Basel, Switzerland)
12. Polycystic Kidney Disease Diet: What is Known and What is Safe.
    Fouad T Chebib, Kristen L Nowak, Michel B Chonchol, Kristen Bing, Ahmad Ghanem, Frederic F Rahbari-Oskoui, Neera K Dahl, Michal Mrug (2024) - Clinical journal of the American Society of Nephrology : CJASN
13. Postinflammatory hyperpigmentation: etiologic and therapeutic considerations.
    Valerie D Callender, Sharleen St Surin-Lord, Erica C Davis, Marissa Maclin (2011) - American journal of clinical dermatology
14. Metabolic Reprogramming in Autosomal Dominant Polycystic Kidney Disease: Evidence and Therapeutic Potential.
    Kristen L Nowak, Katharina Hopp (2020) - Clinical journal of the American Society of Nephrology : CJASN
15. The Impact of Antioxidants on Vitiligo and Melasma: A Scoping Review and Meta-Analysis.
    Reinhart Speeckaert, Vedrana Bulat, Marijn M Speeckaert, Nanja van Geel (2023) - Antioxidants (Basel, Switzerland)
16. PI3K/mTOR inhibitors promote G6PD autophagic degradation and exacerbate oxidative stress damage to radiosensitize small cell lung cancer.
    Huan Deng, Yamei Chen, Li Wang, Yibi Zhang, Qingqing Hang, Peijing Li, Peng Zhang, Jing Ji, Hai Song, Ming Chen, Ying Jin (2023) - Cell death & disease
17. A Bayesian network meta-analysis of 14 molecules inhibiting UV daylight-induced pigmentation.
    Benoit Muller, Frederic Flament, Hussein Jouni, Peggy Sextius, Romain Tachon, Yang Wang, Hequn Wang, Huixia Qiu, Janney Qiu, David Amar, Caroline Delaunay, Nina G Jablonski, Thierry Passeron (2024) - Journal of the European Academy of Dermatology and Venereology : JEADV
18. Top weapons in skin aging and actives to target the consequences of skin cell senescence.
    Z Draelos, P Bogdanowicz, J-H Saurat (2024) - Journal of the European Academy of Dermatology and Venereology : JEADV
19. The Role and Benefits of Dermocosmetics in Acne Management in Japan.
    Ichiro Kurokawa, Miwa Kobayashi, Yuko Nomura, Masatoshi Abe, Delphine Kerob, Brigitte Dreno (2023) - Dermatology and therapy
20. Sleep deprivation causes gut dysbiosis impacting on systemic metabolomics leading to premature ovarian insufficiency in adolescent mice
    Jiamao Yan, Xiaoyuan Zhang, Kexin Zhu, Mubin Yu, Qingchun Liu (2024)
21. Effect of a Tranexamic Acid, Kojic Acid, and Niacinamide Containing Serum on Facial Dyschromia: A Clinical Evaluation.
    Seemal Desai, Eloisa Ayres, Hana Bak, Megan Manco, Stephen Lynch, Susana Raab, Ana Du, DesTenee Green, Cezary Skobowiat, Janet Wangari-Talbot, Qian Zheng (2019) - Journal of drugs in dermatology : JDD
22. Evolution of the use of antioxidants in anti-ageing cosmetics.
    S Silva, M Ferreira, A S Oliveira, C Magalhães, M E Sousa, M Pinto, J M Sousa Lobo, I F Almeida (2019) - International journal of cosmetic science
23. Niacinamide - mechanisms of action and its topical use in dermatology.
    Johannes Wohlrab, Daniela Kreft (2014) - Skin pharmacology and physiology
24. Treatment of generalized granuloma annulare - a systematic review.
    J Lukács, S Schliemann, P Elsner (2015) - Journal of the European Academy of Dermatology and Venereology : JEADV
25. Role of interleukin-6 and endothelin-1 receptors in enhanced melanocyte dendricity of facial spots and suppression of their ligands by niacinamide and tranexamic acid.
    T Hakozaki, J Wang, T Laughlin, B Jarrold, W Zhao, M Furue (2024) - Journal of the European Academy of Dermatology and Venereology : JEADV
26. The role of topical dermocosmetics in acne vulgaris.
    E Araviiskaia, B Dréno (2016) - Journal of the European Academy of Dermatology and Venereology : JEADV
27. Effect of Nicotinamide in Skin Cancer and Actinic Keratoses Chemoprophylaxis, and Adverse Effects Related to Nicotinamide: A Systematic Review and Meta-Analysis.
    Laurence Mainville, Anne-Sophie Smilga, Paul R Fortin (2022) - Journal of cutaneous medicine and surgery
28. Association between Dietary Niacin Intake and Migraine among American Adults: National Health and Nutrition Examination Survey.
    Huanxian Liu, Lu Wang, Chunfu Chen, Zhao Dong, Shengyuan Yu (2022) - Nutrients
29. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients.
    Daniel Keene, Clare Price, Matthew J Shun-Shin, Darrel P Francis (2014) - BMJ (Clinical research ed.)
30. Biological and therapeutic properties of bee pollen: a review.
    Bożena Denisow, Marta Denisow-Pietrzyk (2016) - Journal of the science of food and agriculture
31. Dietary Niacin Intake and Mortality Among Individuals With Nonalcoholic Fatty Liver Disease.
    Jie Pan, Yujia Zhou, Nengzhi Pang, Lili Yang (2024) - JAMA network open
32. The Influence of Nicotinamide on Health and Disease in the Central Nervous System.
    Rosemary A Fricker, Emma L Green, Stuart I Jenkins, Síle M Griffin (2018) - International journal of tryptophan research : IJTR
33. The Promise of Niacin in Neurology.
    Emily Wuerch, Gloria Roldan Urgoiti, V Wee Yong (2023) - Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
34. Supplemental Vitamins and Minerals for CVD Prevention and Treatment.
    David J A Jenkins, J David Spence, Edward L Giovannucci, Young-In Kim, Robert Josse, Reinhold Vieth, Sonia Blanco Mejia, Effie Viguiliouk, Stephanie Nishi, Sandhya Sahye-Pudaruth, Melanie Paquette, Darshna Patel, Sandy Mitchell, Meaghan Kavanagh, Tom Tsirakis, Lina Bachiri, Atherai Maran, Narmada Umatheva, Taylor McKay, Gelaine Trinidad, Daniel Bernstein, Awad Chowdhury, Julieta Correa-Betanzo, Gabriella Del Principe, Anisa Hajizadeh, Rohit Jayaraman, Amy Jenkins, Wendy Jenkins, Ruben Kalaichandran, Geithayini Kirupaharan, Preveena Manisekaran, Tina Qutta, Ramsha Shahid, Alexis Silver, Cleo Villegas, Jessica White, Cyril W C Kendall, Sathish C Pichika, John L Sievenpiper (2018) - Journal of the American College of Cardiology
35. Dietary Supplement Use and Its Micronutrient Contribution During Pregnancy and Lactation in the United States.
    Shinyoung Jun, Jaime J Gahche, Nancy Potischman, Johanna T Dwyer, Patricia M Guenther, Katherine A Sauder, Regan L Bailey (2020) - Obstetrics and gynecology
36. Existing and emerging strategies to lower Lipoprotein(a).
    Gregory G Schwartz, Christie M Ballantyne (2022) - Atherosclerosis
37. Biased allosteric activation of ketone body receptor HCAR2 suppresses inflammation.
    Chang Zhao, Heli Wang, Ying Liu, Lin Cheng, Bo Wang, Xiaowen Tian, Hong Fu, Chao Wu, Ziyan Li, Chenglong Shen, Jingjing Yu, Shengyong Yang, Hongbo Hu, Ping Fu, Liang Ma, Chuanxin Wang, Wei Yan, Zhenhua Shao (2023) - Molecular cell
38. Association between Dietary Niacin Intake and Nonalcoholic Fatty Liver Disease: NHANES 2003-2018.
    Jie Pan, Yuhua Hu, Nengzhi Pang, Lili Yang (2023) - Nutrients
39. Association of niacin intake and metabolic dysfunction-associated steatotic liver disease: findings from National Health and Nutrition Examination Survey.
    Jing Zhou, Jun Han (2024) - BMC public health
40. Supplemental Vitamins and Minerals for Cardiovascular Disease Prevention and Treatment.
    David Perez Ingles, Jose B Cruz Rodriguez, Hernando Garcia (2020) - Current cardiology reports
41. Effect of Niacin on Inflammation and Angiogenesis in a Murine Model of Ulcerative Colitis.
    Hesham Aly Salem, Walaa Wadie (2017) - Scientific reports
42. Association between Daily Niacin Intake and Glaucoma: National Health and Nutrition Examination Survey.
    Teerajet Taechameekietichai, Sunee Chansangpetch, Pimnara Peerawaranun, Shan C Lin (2021) - Nutrients
43. Association between niacin and mortality among patients with cancer in the NHANES retrospective cohort.
    Hongan Ying, Lijie Gao, Nansheng Liao, Xijuan Xu, Wenfeng Yu, Weiwen Hong (2022) - BMC cancer
44. Associations Between Niacin Intake and Glaucoma in the National Health and Nutrition Examination Survey.
    Samuel Y Lee, Victoria L Tseng, Ken Kitayama, Thomas J Avallone, Fei Yu, Deyu Pan, Joseph Caprioli, Anne L Coleman (2023) - Journal of glaucoma
45. Niacin Attenuates Pulmonary Hypertension Through H-PGDS in Macrophages.
    Daile Jia, Peiyuan Bai, Naifu Wan, Jiao Liu, Qian Zhu, Yuhu He, Guilin Chen, Jing Wang, Han Chen, Chen Wang, Ankang Lyu, Michael Lazarus, Yunchao Su, Yoshihiro Urade, Ying Yu, Jian Zhang, Yujun Shen (2020) - Circulation research
46. Effects of NAD+ precursor supplementation on glucose and lipid metabolism in humans: a meta-analysis
    Ou Zhong, Jinyuan Wang, Yongpeng Tan, Xiaocan Lei, Zhihan Tang (2022)
47. Topical 4% nicotinamide vs. 1% clindamycin in moderate inflammatory acne vulgaris
    Effat Khodaeiani, Rohollah Fadaei Fouladi, Mehdi Amirnia, Majid Saeidi, Elham Razagh Karimi (2013)
48. Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris
    A R Shalita, J G Smith, L C Parish, M S Sofman, D K Chalker (1995)
49. 1-Methylnicotinamide: a potent anti-inflammatory agent of vitamin origin
    Jerzy Gebicki, Anna Sysa-Jedrzejowska, Jan Adamus, Anna Woźniacka, Małgorzata Rybak (2003)
50. Niacinamide: A B vitamin that improves aging facial skin appearance
    Donald L Bissett, John E Oblong, Cynthia A Berge (2005)
51. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer
    T Hakozaki, L Minwalla, J Zhuang, M Chhoa, A Matsubara (2002)
52. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD)
    Marinella Ruospo, Suetonia C Palmer, Patrizia Natale, Jonathan C Craig, Mariacristina Vecchio (2018)
53. The Role of Nicotinamide as Chemo-Preventive Agent in NMSCs: A Systematic Review and Meta-Analysis
    Giulio Tosti, Francesca Pepe, Patrizia Gnagnarella, Flavia Silvestri, Aurora Gaeta (2023)

Upload Whole Genome Sequencing (WGS) raw DNA data today and take a deep dive into your genome!

This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.

Or if you only have standard microarray data currently, upload raw DNA data to get started with your free DNA raw data analysis today!